RT Journal Article
SR Electronic
T1 P-010 Endovascular thrombectomy with or without bridging thrombolysis in acute ischemic stroke: a cost-effectiveness analysis
JF Journal of NeuroInterventional Surgery
JO J NeuroIntervent Surg
FD BMJ Publishing Group Ltd.
SP A61
OP A62
DO 10.1136/jnis-2023-SNIS.82
VO 15
IS Suppl 1
A1 R Morsi
A1 Y Zhang
A1 M Zhu
A1 S Xie
A1 J Carrión-Penagos
A1 H Desai
A1 E Tannous
A1 S Kothari
A1 A Khamis
A1 A Darzi
A1 A Tarabichi
A1 R Bastin
A1 L Hneiny
A1 S Thind
A1 J Siegler
A1 E Coleman
A1 S Mendelson
A1 A Mansour
A1 S Prabhakaran
A1 T Kass-Hout
YR 2023
UL http://jnis.bmj.com/content/15/Suppl_1/A61.2.abstract
AB Background There is unclear added benefit of intravenous thrombolysis (IVT) with endovascular thrombectomy (EVT). We performed a cost-effectiveness analysis to assess the cost-effectiveness comparing EVT with IVT versus EVT alone.Methods We used a decision tree to examine the short-term costs and outcomes at 90 days after the occurrence of index stroke to compare the cost-effectiveness of EVT alone with EVT plus IVT for patients with stroke. Subsequently, we developed a Markov state transition model to assess the costs and outcomes over 1-year, 5-year, and 20-year time horizons. Treatment costs and clinical outcome inputs were derived from administrative data and literature included in our systematic review, respectively. We estimated total and incremental cost, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER), expressed as an incremental cost per QALY gained of EVT with IVT compared with EVT alone. We calculated the reference case estimates through probabilistic analysis.Results The average costs per patient were estimated to be $47,304, $49,510, $59,770 and $ 76,561 for EVT only strategy, and $55,482, $57,751, $68,314, and $85,611 for EVT with IVT over 90-day, 1-year, 5-year, and 20-year, respectively. The cost saving of EVT only strategy was driven by the avoided medication costs of IVT (ranging from $8,178 to $9,050). The additional IVT led to a slight decrease in QALY estimate during the 90-day time horizon (loss of 0.002 QALY), but a small gain over 1-year and 5-year time horizons (0.011, and 0.0636 QALY). At a willingness-to-pay threshold of $50,000 per QALY gained, the probabilities of EVT only to be cost-effective were 100%, 100%, and 99.3% over 90-day, 1-year, and 5-year time horizons.Conclusion Our cost-effectiveness model suggested that EVT only may be cost-effective for patients with acute ischemic stroke secondary to large vessel occlusion.Disclosures R. Morsi: None. Y. Zhang: None. M. Zhu: None. S. Xie: None. J. Carrión-Penagos: None. H. Desai: None. E. Tannous: None. S. Kothari: None. A. Khamis: None. A. Darzi: None. A. Tarabichi: None. R. Bastin: None. L. Hneiny: None. S. Thind: None. J. Siegler: None. E. Coleman: None. S. Mendelson: None. A. Mansour: None. S. Prabhakaran: None. T. Kass-Hout: None.